Cancer

Collaboration with Richard Wolf GmbH to develop PVP hypericin

Published in Medical Patent Week, April 8th, 2007

Sanochemia Pharmazeutika AG, Vienna, listed in the Prime Segment of the Frankfurt Stock Exchange (ISIN AT0000776307), has signed a deal with Richard Wolf GmbH (based in Knittlingen, Germany) for the clinical development of its novel diagnostic for early-stage carcinomas.

Richard Wolf GmbH is one of the world's leading companies in the development and manufacture of endoscopic instruments for diagnostic and therapeutic purposes. The agreement concerns the use of the new WOLF Combilight PDD system in the course of a multi-centre clinical trial investigating the fluorescence-based diagnosis of bladder cancer with PVP hypericin. This highly developed endoscopic technique...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Patent Week

Source: Medical Patent Week (2007-04-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry